What Is Ozempic Made Of? Ingredients Explained

Ozempic’s active ingredient is semaglutide, a lab-engineered version of a hormone your gut naturally produces called GLP-1. But the finished product in the injection pen is more than just semaglutide. It contains a handful of inactive ingredients that keep the drug stable, sterile, and at the right pH for injection. The story of what Ozempic is made of gets more interesting when you look at the molecular engineering behind semaglutide itself and how each component of the formulation plays a role.

Semaglutide Is a Modified Version of a Natural Hormone

Your small intestine releases a hormone called glucagon-like peptide-1 (GLP-1) after you eat. GLP-1 signals the pancreas to release insulin, slows the rate your stomach empties, and acts on brain circuits that regulate appetite. The problem with natural GLP-1 is that it falls apart within minutes. Enzymes in the bloodstream, particularly one called DPP-4, chew it up almost as soon as it appears. That rapid destruction makes natural GLP-1 useless as a medication on its own.

Semaglutide solves this by taking the basic GLP-1 structure and modifying it in three key places. First, one of the amino acids near the front of the chain (at position 8) is swapped out for a different amino acid that DPP-4 cannot easily cut. Second, an amino acid deeper in the chain (at position 34) is replaced to create an attachment point. Third, a long fatty acid chain is linked to that attachment point through a small chemical spacer. These changes transform a molecule that lasts minutes into one that lasts about a week in the body, with a half-life of roughly 160 hours.¹ That week-long duration is exactly why Ozempic only needs to be injected once every seven days.

Why the Fatty Acid Chain Is the Most Important Modification

Of those three structural changes, the fatty acid attachment does the heaviest lifting. It is a C18 fatty acid, meaning it has an 18-carbon chain, similar in structure to the fatty acids found in everyday dietary fats like stearic acid. This chain is not just dangling uselessly off the molecule. Once semaglutide enters the bloodstream, the fatty acid latches onto a protein called human serum albumin, which is the most abundant protein in blood plasma. Albumin acts like a circulating taxi, carrying the semaglutide molecule around the body and shielding it from being filtered out by the kidneys or broken down by enzymes.²

This binding to albumin is reversible. Semaglutide hitches a ride on albumin, detaches to interact with GLP-1 receptors in the pancreas, gut, and brain, and then reattaches to albumin when it is done. That cycle of binding and releasing stretches the drug’s active life far beyond what the bare peptide could achieve on its own. The approach is not unique to semaglutide; it is a design strategy that other long-acting peptide drugs also use, but the specific spacer and fatty acid combination in semaglutide were chosen to optimize how tightly and how reliably it grabs onto albumin.

In laboratory studies, semaglutide’s particular fatty acid and spacer combination also appears to help the molecules organize into stable clusters in solution, roughly in groups of six or seven molecules. These clusters resist aggregation, meaning the molecules do not clump together and fall out of solution. That physical stability is part of what allows Ozempic to sit in a pen at controlled temperatures for weeks without degrading.³

The Inactive Ingredients in an Ozempic Pen

Semaglutide does the pharmacological work, but it cannot be injected on its own. The solution inside the Ozempic pen contains several inactive ingredients, each with a specific job:

Disodium phosphate dihydrate: A buffering agent that helps keep the solution at the right pH, which is critical for keeping semaglutide from degrading.
Propylene glycol: A solvent that helps dissolve the other components and maintain a consistent solution. It is widely used in injectable medications and food products.
Phenol: A preservative that prevents bacterial growth in the multi-dose pen. Because you use the same pen for multiple injections over several weeks, something needs to keep the remaining solution sterile after each use.
Hydrochloric acid and sodium hydroxide: Used in tiny amounts during manufacturing to adjust the pH to the precise level where semaglutide is most stable.
Water for injection: The base of the solution, a highly purified form of water that meets pharmaceutical standards for sterility and purity.

None of these inactive ingredients are exotic. Disodium phosphate is found in processed foods. Propylene glycol appears in everything from salad dressings to fog machines. Phenol at the concentrations used in injectable pens is well within established safety limits. The formulation is intentionally simple because the real engineering challenge was building semaglutide itself; the vehicle just needs to keep it dissolved, stable, and sterile.

Why pH Matters So Much to Semaglutide Stability

One of the more interesting aspects of the Ozempic formulation is how sensitive semaglutide is to its chemical environment, particularly pH. Research into semaglutide degradation has found that pH is the single most important factor determining how quickly the molecule breaks down under thermal stress. At higher temperatures and unfavorable pH levels, semaglutide can fracture into more than a dozen different degradation fragments as its peptide backbone gets cut and its fatty acid side chain undergoes chemical changes.⁴

This is why the buffering system in the Ozempic pen is not just a nice-to-have. The disodium phosphate dihydrate and the precise pH adjustments made during manufacturing are load-bearing parts of the formulation. Without them, the semaglutide would degrade substantially faster, especially if the pen were ever exposed to warm temperatures. It is also why the storage instructions for Ozempic are relatively strict compared to many oral medications: before first use, the pen should be refrigerated, and after first use, it can be kept at room temperature but should be used within a set time window. Temperature and pH are the two biggest enemies of the molecule.

How Oral Semaglutide Uses a Different Formulation Strategy

Ozempic is an injection, but semaglutide also comes in a daily oral tablet sold as Rybelsus. The active ingredient is identical, the same engineered peptide with the same modifications. What changes entirely is the delivery system, because getting a peptide through the stomach and into the bloodstream is a fundamentally different challenge than injecting it under the skin.

Peptides are proteins, and the stomach is designed to destroy proteins. Gastric acid and digestive enzymes would normally shred semaglutide before it could be absorbed. To get around this, the oral tablet pairs semaglutide with a compound called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate). SNAC does two things: it creates a local buffer around the tablet that raises the pH in its immediate vicinity, protecting semaglutide from the acidic environment, and it enhances absorption by temporarily increasing the permeability of the stomach lining so the peptide can pass through into the bloodstream.⁵

SNAC was the key innovation that made oral semaglutide possible, producing the first orally administered GLP-1 receptor agonist to reach the market.⁶ Even with SNAC’s help, only a small fraction of the semaglutide in each tablet actually makes it into the bloodstream, which is why the oral dose is much higher than the injected dose and why the instructions say to take the tablet on an empty stomach with only a small sip of water. Food or excess liquid in the stomach dilutes the SNAC buffer and interferes with absorption.

How Your Body Breaks Semaglutide Down

Once semaglutide has done its work, your body disposes of it through the same basic machinery it uses to break down other proteins and fats. The peptide backbone is cut apart by proteolytic enzymes, the same class of enzymes that digest the proteins in your food. Meanwhile, the fatty acid side chain undergoes beta-oxidation, a process your cells use routinely to break down fatty acids for energy. Importantly, this breakdown is not concentrated in the liver or kidneys; it happens throughout the body, spread across multiple organs and tissues.⁷

This distributed metabolism is actually one of the reasons semaglutide does not require dose adjustments for people with mild to moderate kidney or liver impairment. Because no single organ is responsible for clearing the drug, reduced function in one organ does not cause the drug to accumulate as dramatically as it would if, say, the kidneys were the sole exit route. The fragments produced during breakdown are eventually excreted in urine and feces.

The Gila Monster Connection

Semaglutide did not appear out of nowhere. It sits at the end of a research lineage that traces back to the venom of the Gila monster, a large venomous lizard native to the southwestern United States and Mexico. In the 1990s, researchers studying Gila monster venom isolated a peptide called exendin-4 that turned out to share about 53% of its structure with human GLP-1. Unlike human GLP-1, exendin-4 was far more resistant to being broken down by DPP-4, the same enzyme that destroys natural GLP-1 within minutes.⁸

That discovery led directly to the development of exenatide (brand name Byetta), which reached the market in 2005 as the first GLP-1 receptor agonist approved for type 2 diabetes. Exenatide was a synthetic copy of the lizard peptide. It worked, but it needed to be injected twice daily because its duration of action, while much longer than native GLP-1, was still relatively short. The next wave of drug development shifted away from copying the lizard peptide and toward modifying human GLP-1 itself, using tricks like fatty acid attachment to extend duration. Liraglutide (Victoza) came next as a once-daily injection, and then semaglutide pushed the approach further to achieve once-weekly dosing.

So while Ozempic does not literally contain lizard venom, the drug exists because a lizard’s venom provided the proof of concept that a GLP-1-like molecule could survive in the bloodstream long enough to be medically useful. Every GLP-1 drug on the market today owes something to that initial discovery.

Compounded Semaglutide Is Not the Same Formulation

One question that comes up frequently, especially given Ozempic’s ongoing supply challenges and high cost, is whether compounded versions of semaglutide are made of the same thing. Compounding pharmacies have been producing their own semaglutide preparations, sometimes using the semaglutide salt form (semaglutide sodium or semaglutide acetate) rather than the base form used in Ozempic. The distinction matters because the salt form has different properties in terms of solubility, stability, and potency by weight. A milligram of semaglutide sodium is not identical in active content to a milligram of semaglutide base.

Compounded formulations also differ in their inactive ingredients. They may use different preservatives, different buffers, or different concentrations. Because compounded drugs are not subject to the same manufacturing controls and batch testing as FDA-approved products, there is more variability between doses and between pharmacies. The FDA has issued warnings about compounded semaglutide products, and the regulatory landscape around them continues to shift. If you are considering a compounded version, the key thing to understand is that while the active molecule may be semaglutide, the total formulation, including the inactive ingredients that affect stability, sterility, and absorption, can differ in ways that matter clinically.

What the Ingredients Do Not Tell You

Reading an ingredient list for a biologic drug like Ozempic can be misleading if you are used to reading food labels or over-the-counter drug labels. Most of the therapeutic action comes from the three-dimensional shape of the semaglutide molecule and the specific way its fatty acid chain interacts with albumin in the blood. You could list every ingredient on the label and still miss what makes the drug work, because the “active ingredient” is not a simple chemical compound like acetaminophen or ibuprofen. It is a 31-amino-acid peptide with a precisely attached lipid tail, and its function depends on how that structure folds, how it binds to receptors, and how it hitches onto albumin for transport. The inactive ingredients exist to preserve that delicate structure until the moment of injection.

This is also why biosimilar versions of semaglutide, when they eventually arrive, will face a much higher bar than generic versions of small-molecule drugs. For a simple chemical like ibuprofen, proving that a generic is identical is straightforward. For a peptide drug, demonstrating that a biosimilar achieves the same folding, the same receptor binding, and the same pharmacokinetic profile requires extensive comparative testing. The ingredients list alone cannot capture those differences.